Home About Us Pipeline News Investors Contacts Careers


News

Recent Press Releases Archives

Recent Press Releases

2020 News Releases

September 8, 2020 - Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Read

September 3, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

August 19, 2020 - Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Read

August 10, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

August 6, 2020 - Puma Biotechnology Reports Second Quarter 2020 Financial Results
Read

July 27, 2020 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers
Read

July 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read

July 16, 2020 - Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Read

July 9, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

June 2, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

May 8, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

May 7, 2020 - Puma Biotechnology Reports First Quarter 2020 Financial Results
Read

May 7, 2020 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Read

May 6, 2020 - Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020
Read

April 30, 2020 - Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
Read

April 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

April 3, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

March 25, 2020 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read

March 5, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

February 28, 2020 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
Read

February 26, 2020 - Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read

February 20, 2020 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read

February 7, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

February 5, 2020 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results
Read

January 13, 2020 - Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference
Read

January 9, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

January 7, 2020 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Read




Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax